Date: 2015-02-02
Type of information: IPO
Company: Ascendis Pharma (Denmark)
Investors:
Amount: $111.5 million
Funding type: IPO
Planned used:
Others: * On February 2, 2015, Ascendis Pharma, a clinical stage biopharmaceutical company, announced the closing of its initial public offering of 6,900,000 American Depositary Shares (ADSs) at a price to the public of $18.00 per ADS, which includes the exercise in full by the underwriters of their option to purchase additional ADSs. Ascendis estimates net proceeds from the offering to be approximately $111.5 million, after deducting underwriting commissions and estimated offering expenses. BofA Merrill Lynch and Leerink Partners LLC acted as joint book-running managers for the offering. Wells Fargo Securities acted as co-manager.
Therapeutic area:
